Shandong Xinhua Pharmaceutical (00719) said its net profit attributable to shareholders for the year ended 31 December 2017 rose 71.42% year-on-year to Rmb209.6 million.
Basic and diluted earnings per share were Rmb0.45.
Operating income amounted to Rmb4,516 million, an increase of 12.47% from a year earlier. Gross profit grew 67.64% year-on-year to Rmb268 million.
The proposed final dividend is Rmb5 cents (tax inclusive) per share, with 3 new shares for every 10 existing shares to be issued out of capital reserve to all shareholders.